Utility of blood procalcitonin concentration in the management of cancer patients with infections

Durnaś, Bonita; Wątek, Marzena; Wollny, Tomasz; Niemirowicz, Katarzyna; Marzec, Michał; Bucki, Robert; Góźdż, Stanisław

doi:10.2147/ott.s95600

Cited by 25 publications

(19 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, more than 170 different biomarkers have been evaluated for use in sepsis complications and outcome prediction, evaluation of therapy response, and development of organ dysfunction [ 95 ]. Despite this number, only a few of them, including C-reactive protein (CRP) [ 96 ] and procalcitonin (PCT) [ 97 , 98 ], are routinely employed in clinical practice due to low specificity or sensitivity of the proposed biomarkers [ 95 , 99 ]. Even CRP and PCT therapeutic values have been challenged due to difficulties in distinguishing sepsis from other inflammatory diseases [ 98 , 100 , 101 ].…”

Section: Alterations In Plasma Gelsolin Concentrations In Differenmentioning

confidence: 99%

Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target

Piktel

Levental

Durnaś

et al. 2018

IJMS

Self Cite

107

View full text Add to dashboard Cite

Gelsolin, an actin-depolymerizing protein expressed both in extracellular fluids and in the cytoplasm of a majority of human cells, has been recently implicated in a variety of both physiological and pathological processes. Its extracellular isoform, called plasma gelsolin (pGSN), is present in blood, cerebrospinal fluid, milk, urine, and other extracellular fluids. This isoform has been recognized as a potential biomarker of inflammatory-associated medical conditions, allowing for the prediction of illness severity, recovery, efficacy of treatment, and clinical outcome. A compelling number of animal studies also demonstrate a broad spectrum of beneficial effects mediated by gelsolin, suggesting therapeutic utility for extracellular recombinant gelsolin. In the review, we summarize the current data related to the potential of pGSN as an inflammatory predictor and therapeutic target, discuss gelsolin-mediated mechanisms of action, and highlight recent progress in the clinical use of pGSN.

show abstract

Section: Alterations In Plasma Gelsolin Concentrations In Differenmentioning

confidence: 99%

Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target

Piktel

Levental

Durnaś

et al. 2018

IJMS

Self Cite

107

View full text Add to dashboard Cite

show abstract

“…This theory is based on the observations that some classes of molecules, along with tissue damage and the resulting inflammation, increase cell proliferation. Certainly, the promotion of cancer risk is due not only to cell proliferation but also due to prolonged cell proliferation in an environment containing inflammatory cells, cytokines, activated stroma, and agents promoting DNA damage [ 65 , 66 ].…”

Section: What Induces Cancerogenesis In Gd?mentioning

confidence: 99%

Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links Between Gaucher Disease and Blood Cancer Development

Wątek

Piktel

Wollny

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

There is a rising number of evidence indicating the increased risk of cancer development in association with congenital metabolic errors. Although these diseases represent disorders of individual genes, they lead to the disruption of metabolic pathways resulting in metabolite accumulation or their deficiency. Gaucher disease (GD) is an autosomal recessive sphingolipidosis. It is a rare lysosomal storage disease. A strong correlation between GD and different types of cancers, such as multiple myeloma, leukemia, and hepatocellular carcinoma, has been reported. Common features for all types of GD include spleen and liver enlargement, cytopenia, and a variety of bone defects. Overall, the molecular bases leading to the association of GD and cancers are not clearly understood. Here, we describe the role of ceramides in GD, discuss the potential implications of immune cells activation and show how the disturbances in their metabolism might promote blood cancer development.

show abstract

“…In patients with cancer, a diagnosis of infection is usually problematic. The clinical challenge is to differentiate infection and fever of unknown importance [21]. Early diagnosis and stratification of sepsis risk increases the chances of initiating well-timed treatment, which improves the prognosis of patients [22].…”

Section: Discussionmentioning

confidence: 99%

Hypogelsolinemia in Patients Diagnosed with Acute Myeloid Leukemia at Initial Stage of Sepsis

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background Gelsolin (GSN) is an actin-binding and PIP 2 /Ca 2+ -regulated protein found in the cytoplasm and blood plasma. Hypogelsolinemia occurs in a wide range of traumatic injuries and inflammatory reactions. We hypothesize that blood GSN levels will be altered in patients diagnosed with acute myeloid leukemia (AML) that develop sepsis, and assessment of GSN concentration will be a useful marker to determine their clinical outcome. To achieve this task, we evaluated the plasma gelsolin concentration in blood samples collected from patients diagnosed with acute myeloid leukemia (AML) at initial stages of sepsis. Material/Methods To assess if AML patients might be at risk of sepsis, a SOFA score was determined. Plasma gelsolin concentration was evaluated using an immunoblotting technique. Results We found that GSN concentration in the blood of the AML group with developing sepsis was significantly lower (32±41 μg/ml; p<0.05) compared to the AML group (65±35 μg/ml) and control group (176±37 μg/ml; p<0.001). Additionally, low gelsolin concentration in the blood of AML patients developing sepsis was associated with a high SOFA score. A decrease of GSN concentration in the blood of AML subjects with developing sepsis suggests that GSN level in blood reflects not only chronic inflammation stage associated with leukemia, but that GSN depletion also manifests the inflammation associated with sepsis development. Conclusions The results presented here suggest the possible utility of GSN evaluation for diagnostic purposes. Overall, these data support the that reversing plasma GSN deficiency might be a possible new strategy in sepsis treatment.

show abstract

Utility of blood procalcitonin concentration in the management of cancer patients with infections

Cited by 25 publications

References 45 publications

Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target

Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target

Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links Between Gaucher Disease and Blood Cancer Development

Hypogelsolinemia in Patients Diagnosed with Acute Myeloid Leukemia at Initial Stage of Sepsis

Contact Info

Product

Resources

About